Literature DB >> 359390

The effect of E. coli L-asparaginase on oral glucose tolerance and insulin release in man.

R L Lavine, I Brodsky, C D Garofano, L I Rose.   

Abstract

To study the effect of E. Coli L-asparaginase on glucose tolerance and insulin release, 6 patients with neoplastic disease were subjected to 3 hour oral glucose tolerance tests with simultaneous measurement of serum immunoreactive insulin (IRI) levels before and following the intravenous administration of 5000 I. U. L-asparaginase/day for 4 days. Five of the patients exhibited a significant deterioration in glucose tolerance; however, no change was noted in their fasting glucose and IRI levels. The deterioration in glucose tolerance was associated with a decrease in the amount of insulin secreted in the first 30 minutes after the oral glucose load. The total amount of insulin released during the 3 hour test remained unchanged. These studies suggest that L-asparaginase can cause a deterioration of glucose tolerance without accompanying fasting hyperglycaemia. This may be due, in part, to a decrease in glucose-induced insulin release during the first thirty minutes following oral glucose.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 359390     DOI: 10.1007/bf00422255

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  19 in total

1.  Glucose tolerance and diabetes in chronic liver disease.

Authors:  C Megyesi; E Samols; V Marks
Journal:  Lancet       Date:  1967-11-18       Impact factor: 79.321

2.  Relationship between intravenous glucose loads, insulin responses and glucose disappearance rate.

Authors:  R L Lerner; D Porte
Journal:  J Clin Endocrinol Metab       Date:  1971-09       Impact factor: 5.958

Review 3.  L-asparaginase.

Authors:  J P Whitecar; G P Bodey; J E Harris; E J Freireich
Journal:  N Engl J Med       Date:  1970-03-26       Impact factor: 91.245

4.  Effect of transient elevation of plasma insulin within physiologic levels (simulated early insulin response) on blood glucose.

Authors:  J I Thorell
Journal:  J Clin Endocrinol Metab       Date:  1973-09       Impact factor: 5.958

5.  Transient diabetes mellitus secondary to L-asparaginase therapy in acute leukemia.

Authors:  P C Gillette; L L Hill; K A Starling; D J Fernbach
Journal:  J Pediatr       Date:  1972-07       Impact factor: 4.406

6.  Diabetes in patients treated with asparaginase.

Authors:  S Gailani; A Nussbaum; T Onuma; A Freeman
Journal:  Clin Pharmacol Ther       Date:  1971 May-Jun       Impact factor: 6.875

7.  Solid-phase radioimmunoassay of insulin.

Authors:  M Ceska; F Grossmüller; U Lundkvist
Journal:  Acta Endocrinol (Copenh)       Date:  1970-05

8.  L-asparaginase toxicity.

Authors:  C M Haskell; G P Canellos; B G Leventhal; P P Carbone; A A Serpick; H H Hansen
Journal:  Cancer Res       Date:  1969-04       Impact factor: 12.701

9.  Glucose and lactate kinetics after endotoxin administration in dogs.

Authors:  R R Wolfe; D Elahi; J J Spitzer
Journal:  Am J Physiol       Date:  1977-02

10.  Nonketotic hyperglycemia due to prednisone (NSC-10023) following ketotic hyperglycemia due to L-asparaginase (NSC-109229) plus prednisone.

Authors:  J M Falletta; C P Steuber; J W Hayes; K A Starling; L L Hill
Journal:  Cancer Chemother Rep       Date:  1972-12
View more
  2 in total

1.  Transient secondary hypothyroidism and thyroxine binding globulin deficiency in leukemic children during polychemotherapy: an effect of L-asparaginase.

Authors:  P H Heidemann; P Stubbe; W Beck
Journal:  Eur J Pediatr       Date:  1981-07       Impact factor: 3.183

2.  Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia.

Authors:  J R Roberson; H L Spraker; J Shelso; Y Zhou; H Inaba; M L Metzger; J E Rubnitz; R C Ribeiro; J T Sandlund; S Jeha; C-H Pui; S C Howard
Journal:  Leukemia       Date:  2008-10-16       Impact factor: 11.528

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.